$5.93
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis
Overview
52-week range
$5.85
$24
0% of range
Avg surprise (last 3)
+51.0%
Avg reaction (last 2)
+1.5%
50% positive
Latest IV / EM
29%
EM ±6.7% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.95 | $-1.14 | +16.7% | -82.7% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.49 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.34 | $-1.11 | +69.4% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.52 | $-1.58 | +67.1% | — | +5.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.26 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.64 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.00 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.61 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.98 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$1.07 | -$0.34 | -214.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | — | $17M | $28M | $29M | — | $42M | $50M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-29M | — | $-17M | $-12M | $-17M | — | $-11M | $-21M |
| Net income | $-27M | — | $-13M | $-9M | $-14M | — | $-7M | $-17M |
| EPS (diluted) | $-0.95 | — | $-0.49 | $-0.34 | $-0.52 | — | $-0.26 | $-0.64 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $211M | $231M | $180M | $196M | $217M | $237M | $237M | $260M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $217M | $241M | $249M | $275M | $279M | $306M | $331M | $347M |
| Total assets | $245M | $271M | $282M | $309M | $332M | $344M | $371M | $389M |
| Long-term debt | — | — | — | — | $15M | — | — | — |
| Total liabilities | $54M | $57M | $58M | $78M | $98M | $103M | $109M | $130M |
| Total equity | $191M | $214M | $225M | $231M | $234M | $241M | $262M | $259M |